key: cord-0811784-qaeygzns
authors: Li, Zheng‐tu; Chen, Zhao‐ming; Chen, Ling‐dan; Zhan, Yang‐qing; Li, Shao‐qiang; Cheng, Jing; Zhu, Ai‐ru; Chen, Li‐yan; Zhong, Nan‐shan; Li, Shi‐yue; Lu, Wen‐ju; Ye, Feng
title: Coinfection with SARS‐CoV‐2 and other respiratory pathogens in COVID‐19 patients in Guangzhou, China
date: 2020-05-28
journal: J Med Virol
DOI: 10.1002/jmv.26073
sha: fb88c18ed279fbd35c2b156075658e6062d9dc13
doc_id: 811784
cord_uid: qaeygzns

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; previously provisionally named 2019 novel coronavirus or 2019‐nCoV) disease (COVID‐19) in China at the end of 2019 has caused a global pandemic and remains as a major public health issue This article is protected by copyright. All rights reserved.

pandemic and remains as a major public health issue. 1 As of 20 May 2020, data from the World Health Organization (WHO) have shown that more than 4,735,622 confirmed cases have been identified in 216 countries/regions. 2 Previous studies have found that the immune system is damaged when the human body is infected with influenza virus, which may lead to coinfection of bacteria and even secondary fungal coinfection, with high mortality 3, 4, 5, 6 Cases of coinfection with SARS-CoV-2 and other respiratory pathogens have also been recently reported in China. 7, 8 We herein report 14 cases of COVID-19 coinfected with other respiratory pathogens and compare the clinical characteristics and laboratory results of COVID-19 patients with or without coinfection in Guangzhou, China.

In this study, we included 32 confirmed COVID-19 cases between January 1, 2020 and March 1, 2020. Demographic, clinical, and radiological features and laboratory data were collected. Pathogenic species in sputum specimens which were collected from 10 to 25 days of onset of symptoms and single sample from each patient, were identified by RT-PCR and culture. Among these cases, 14 patients were infected with other pathogens, including viral, bacterial and fungal infections. Five cases were infected with respiratory syncytial virus (RSV), human parainfluenza virus (HPIV), human metapneumovirus (hMPV), rhinoviruso (rRhV) and enterovirus (EV) (Table S1), which are prevalent in children and infants; however, these viruses are also common in adults with immunodeficiency. Whether infections by these viruses were also due to immunodeficient state of COVID-19 patients was unclear. Moreover, we found two interesting cases of coinfection with CoV-HKU1 (Table S1) , which is a This article is protected by copyright. All rights reserved.

β-coronavirus A strain and has a genome structure that is similar to that of other coronaviruses of the β group, and has been previously reported. 4, 9 This indicates that this subject was simultaneously infected with two different β-group coronaviruses. Ten COVID-19 patients (31%) were infected with opportunistic pathogenic bacteria, including gram-negative bacteria Staphylococcus epidermidis and Acinetobacter baumannii. Candida albicans infection was also common among these patients (Table S1 ). This finding suggests that we need to pay additional attention to the possibility of secondary infections in severe patients and take appropriate measures to prevent the occurrence of this situation.

Our results showed that the proportion of ICU patients in COVID-19 patients with other respiratory pathogen infections was significantly higher than those without other respiratory pathogen infections (P˂0.05) ( Table 1 ). The differences of symptoms between the two groups were manifested mainly in the breathing of patients, and COVID-19 patients with coinfections presented with more severe difficulty in breathing (P˂0.05) (Table 1) . Additionally, COVID-19 patients with coinfection were more likely to have complications such as acute respiratory distress syndrome (ARDS) and shock (P<0.05) ( Table 1 ). The CT images of COVID-19 patients with coinfection were more complicated and diverse, and were different from those of patients without coinfection.

Further comparison of laboratory results between COVID-19 patients with and without coinfection showed that lymphocyte and platelet counts of coinfected patients with the novel coronavirus were significantly lower than those of patients without coinfection (P<0.05) (Table S2) , and lymphocytopenia was identified as a risk factor for coinfection during COVID-19 (Table S3 ). Since the outbreak of This article is protected by copyright. All rights reserved.

COVID-19, a significant reduction in lymphocyte counts in peripheral blood has been clinically observed in many cases of COVID-19, which has been listed as one of the laboratory indicators by clinical guidelines. 10, 11, 12 A study of 1,099 COVID-19 patients showed that lymphocytopenia was present in 83.2% of the patients on admission. 13 Lymphocytes play an important role in the body's adaptive immunity against a variety of pathogens. The emergence of lymphocytopenia in COVID-19 patients results in a state of immunodeficiency, which makes it easier to be coinfected with other respiratory pathogens, including viruses, bacteria, and even fungi. A recent preprint study showed that human primary peripheral blood monocytes (PBMCs) are not susceptible to SARS-CoV-2 because viral replication was not detected in human immune cells.

Interestingly, SARS-CoV-2 virus-like particles were observed in primary CD4+ T cells by electron microscopy. 14 Sepsis leads to large amounts of pro-inflammatory and anti-inflammatory cytokines, which induce reduced lymphocyte apoptosis and chronic immune responses. 15 The cause of lymphocytic reduction in COVID-19 patients may be related to the excessive immune response and cytokine storm.

In summary, we must be alert to the occurrence of coinfection in COVID-19 patients, especially in severe ICU patients. Lymphocytopenia may play an important role in the occurrence of coinfection, which deserves additional research to explore its potential mechanisms and the impact on the pathogenesis of COVID-19 patients.

1. Lai C, Shih T, Ko 

COVID-19): The epidemic and the challenges

COVID-19) outbreak situation

Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States

Coinfection with COVID-19 and Coronavirus HKU1 -the critical need for repeat testing if clinically indicated

Co-detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease-2019 pneumonia

Co-infection in SARS-CoV-2 infected Patients: Where Are Influenza Virus and Rhinovirus/Enterovirus?

The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan

COVID-19 Associated Pulmonary Aspergillosis

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

Prevention CCfDCa. The guideline of diagnosis and treatment of COVID-19

Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis

Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19

Clinical Characteristics of Covid-19 in China. Reply